Patents by Inventor Kyle HAVENS

Kyle HAVENS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDCD-1 HOMING ENDONUCLEASE VARIANTS
    Publication number: 20260159820
    Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene. The present disclosure relates to genome editing compositions with improved stability and activity. More particularly, the disclosure relates to improved nuclease variants, compositions, and methods of using the same for editing the human program cell death (PDCD-1) gene.
    Type: Application
    Filed: February 12, 2026
    Publication date: June 11, 2026
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Jasdeep MANN
  • PDCD-1 homing endonuclease variants
    Patent number: 12577547
    Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: March 17, 2026
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Jasdeep Mann
  • HOMING ENDONUCLEASE VARIANTS
    Publication number: 20250368973
    Abstract: The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.
    Type: Application
    Filed: August 19, 2025
    Publication date: December 4, 2025
    Applicant: Novo Nordisk A/S
    Inventors: Jordan JARJOUR, Kyle HAVENS, Constantine CHRYSOSTOMOU
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20250327049
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: April 22, 2025
    Publication date: October 23, 2025
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • Homing endonuclease variants
    Patent number: 12404500
    Abstract: The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 2, 2025
    Assignee: NOVO NORDISK A/S
    Inventors: Jordan Jarjour, Kyle Havens, Constantine Chrysostomou
  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20250262323
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: April 21, 2025
    Publication date: August 21, 2025
    Applicant: Novo Nordisk A/S
    Inventors: Jordan JARJOUR, Kyle HAVENS, Michael CERTO, Max ECHTERLING
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20250179469
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a casitas B-lineage (Cbl) lymphoma proto-oncogene B (CBLB) gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: February 13, 2025
    Publication date: June 5, 2025
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 12297465
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: May 13, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 12227740
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: February 18, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20240189454
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: August 30, 2023
    Publication date: June 13, 2024
    Applicant: 2Seventy bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Michael CERTO, Max ECHTERLING
  • PCSK9 endonuclease variants, compositions, and methods of use
    Patent number: 11779654
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 10, 2023
    Assignee: 2SEVENTY BIO, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Michael Certo, Max Echterling
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 11732255
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 22, 2023
    Assignee: 2seventy bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • TGFBetaR2 endonuclease variants, compositions, and methods of use
    Patent number: 11530395
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a TGF?R2 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 20, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens
  • PDCD-1 HOMING ENDONUCLEASE VARIANTS
    Publication number: 20220177860
    Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 9, 2022
    Applicant: 2Seventy bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, JASDEEP MANN
  • HOMING ENDONUCLEASE VARIANTS
    Publication number: 20220119784
    Abstract: The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 21, 2022
    Applicant: 2seventy bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, CONSTANTINE CHRYSOSTOMOU
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210214700
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210214714
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210147818
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 20, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 10927367
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: February 23, 2021
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • CTLA4 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210002621
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CTLA4 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: December 20, 2018
    Publication date: January 7, 2021
    Applicant: bluebird bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS